Jean-Charles Soria to Biomarkers, Tumor
This is a "connection" page, showing publications Jean-Charles Soria has written about Biomarkers, Tumor.
Connection Strength
2.092
-
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034.
Score: 0.361
-
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. Eur J Cancer. 2017 09; 83:185-193.
Score: 0.356
-
Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2017; 37:12-17.
Score: 0.343
-
[Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention]. Bull Cancer. 2001 Apr; 88(4):351-61.
Score: 0.115
-
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 10 20; 36(30):2995-3006.
Score: 0.096
-
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
Score: 0.093
-
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018 03; 92:1-10.
Score: 0.092
-
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017; 12(11):e0188174.
Score: 0.091
-
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017 12; 87:122-130.
Score: 0.091
-
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 07; 109:101-108.
Score: 0.088
-
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res. 2017 05 01; 77(9):2222-2230.
Score: 0.088
-
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res. 2016 Sep 01; 22(17):4309-21.
Score: 0.083
-
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol. 2016 Jan; 36(1):94-102.
Score: 0.080
-
LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):66-73.e6.
Score: 0.024
-
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018 09; 19(9):1180-1191.
Score: 0.024
-
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017 10; 112:62-68.
Score: 0.022
-
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017 10; 112:10-15.
Score: 0.022
-
Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017 Oct 15; 23(20):6101-6112.
Score: 0.022